CG Oncology officer plans $2.3M stock sale

CG Oncology, Inc. (CGON) has a notice under Rule 144 from officer Ambaw Bellete covering the proposed sale of 29,630 shares of common stock, expected to be sold on September 2, 2026 following a stock option exercise, through Morgan Stanley Smith Barney LLC.

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) has a notice under Rule 144 from officer Ambaw Bellete covering the proposed sale of 29,630 shares of common stock, expected to be sold on September 2, 2026 following a stock option exercise, through Morgan Stanley Smith Barney LLC.

The notice lists an aggregate market value for these planned sales of $2,299,448.00, and states that CG Oncology had 88,640,375 shares of common stock outstanding. It also details multiple prior open-market sales by Ambaw Bellete over the past three months, including several blocks of 50,000–100,000 shares.

Key Figures

Shares to be sold under Rule 144: 29,630 shares Aggregate market value of planned sale: $2,299,448.00 Shares of common stock outstanding: 88,640,375 shares +3 more

6 metrics

Shares to be sold under Rule 144 29,630 shares Common stock proposed for sale on September 2, 2026 by officer Ambaw Bellete

Aggregate market value of planned sale $2,299,448.00 Value associated with the 29,630 shares covered by the Rule 144 notice

Shares of common stock outstanding 88,640,375 shares CG Oncology common shares outstanding as referenced in the Rule 144 notice

Single largest recent sale 100,000 shares for $7,954,105.00 Sale of CG Oncology common stock on August 19, 2026 by Ambaw Bellete

Example recent 50,000-share sale 50,000 shares for $3,810,255.00 Sale of CG Oncology common stock on August 11, 2026 by Ambaw Bellete

Additional 50,000-share sale 50,000 shares for $3,625,195.00 Sale of CG Oncology common stock on July 28, 2026 by Ambaw Bellete

Key Terms

Rule 144, stock option exercise, aggregate market value, securities to be sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 09/02/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 29630 | 2299448.00 | 88640375"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold regulatory

"Name of Person for Whose Account the Securities are To Be Sold"

FAQ

What does CGON’s latest Rule 144 filing disclose about Ambaw Bellete’s planned stock sale?

The Rule 144 notice states that officer Ambaw Bellete plans to sell 29,630 shares of CG Oncology common stock on September 2, 2026 following a stock option exercise, with the transaction to be handled in cash through Morgan Stanley Smith Barney LLC.

How large is Ambaw Bellete’s planned CGON share sale in dollar terms?

The filing lists an aggregate market value of $2,299,448.00 for the planned sale of 29,630 CG Oncology common shares covered by the Rule 144 notice dated September 2, 2026.

How many CGON shares were outstanding according to this Rule 144 filing?

The Rule 144 disclosure states that CG Oncology had 88,640,375 shares of common stock outstanding at the time referenced. This figure is presented alongside the proposed Rule 144 sale amount and serves as an overall share-count context.

What recent CGON stock sales by Ambaw Bellete are listed in the past three months?

The filing lists multiple sales of CG Oncology common stock by Ambaw Bellete in the prior three months, including 100,000 shares on August 19, 2026 for $7,954,105.00 and several 50,000-share blocks sold between July and August 2026.

Through which broker will Ambaw Bellete’s CGON Rule 144 sale be executed?

The planned sale of 29,630 CG Oncology common shares is designated to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, according to the Rule 144 notice.

What is the relationship of Ambaw Bellete to CG Oncology (CGON) in this filing?

Ambaw Bellete is identified as an Officer of CG Oncology, Inc. in the Rule 144 notice, and the securities to be sold consist of common stock acquired via a stock option exercise from the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 05:03 PM Accepted by SEC EDGAR 09/02/2026 - 05:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002007090
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CG ONCOLOGY, INC.
SEC File Number	001-41925
Address of Issuer	3000 Pegasus Park Drive SUITE 1640 Dallas TEXAS 75247
Phone	(949) 409-3700
Name of Person for Whose Account the Securities are To Be Sold	AMBAW BELLETE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	29630	2299448.00	88640375	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	Stock Option Exercise	Issuer			29630	09/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/31/2026	50000	3775250.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/27/2026	5789	459560.92
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/25/2026	10551	839338.38
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/24/2026	5762	458185.02
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/19/2026	100000	7954105.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/17/2026	52438	4034894.35
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/14/2026	19364	1452635.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/13/2026	25989	1973970.86
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/12/2026	32137	2526514.53
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/11/2026	50000	3810255.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/10/2026	50000	3770580.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/07/2026	9250	696062.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/06/2026	75000	5672212.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/05/2026	25000	1837500.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/29/2026	4303	316270.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/28/2026	50000	3625195.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/27/2026	50000	3627995.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/23/2026	50000	3588620.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/15/2026	52438	3816007.65

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ambaw Bellete
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)